YMI024
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 21, 2026
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
(clinicaltrials.gov)
- P2 | N=180 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P2 trial • Cardiovascular • Coronary Artery Disease
1 to 1
Of
1
Go to page
1